A personalized paradigm in the treatment of platinum-resistant ovarian cancer: a cost utility analysis of genomic-based versus cytotoxic therapy

Forde, Braxton

54
A personalized paradigm in the treatment of platinum-resistant ovarian cancer: a cost utility analysis of genomic-based versus cytotoxic therapy

Tuesday, March 31, 2015: 8:38 AM

International Ballroom (Hilton Chicago)

B. Forde¹, J. Wallbillich¹, L. J. Havrilesky² and D. E. Cohn¹
¹The Ohio State University, Columbus, OH, ²Duke University School of Medicine, Durham, NC

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

54
A personalized paradigm in the treatment of platinum-resistant ovarian cancer: a cost utility analysis of genomic-based versus cytotoxic therapy

54 A personalized paradigm in the treatment of platinum-resistant ovarian cancer: a cost utility analysis of genomic-based versus cytotoxic therapy

54
A personalized paradigm in the treatment of platinum-resistant ovarian cancer: a cost utility analysis of genomic-based versus cytotoxic therapy